177Lu-EDTMP: A viable bone pain palliative in skeletal metastasis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 2, 2008, Pages 202-213

  Chakraborty, Sudipta ^a   Das, Tapas ^a   Banerjee, Sharmila ^a   Balogh, Lajos ^b   Chaudhari, Pradip R ^a   Sarma, Haladhar D ^a   Polyák, András ^b   Máthé, Domokos ^b   Venkatesh, Meera ^a   Janoki, Gyõzõ ^b   Pillai, Maroor R A ^c  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^c INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

177Lu; Bone pain palliation; EDTMP; Skeletal metastasis

Indexed keywords

ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; LUTETIUM 177; PHOSPHONIC ACID DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; NEUTRON RADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PALLIATIVE THERAPY; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SCINTIGRAPHY; SUSTAINED RELEASE PREPARATION; ANIMAL; BONE TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DOG; INFRARED SPECTROSCOPY; METASTASIS; PAIN; RABBIT; RADIOGRAPHY;

ANIMALS; BONE NEOPLASMS; DOGS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RABBITS; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 43049123466     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.374     Document Type: Article

References (41)

1. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987;28:495.
2. McEwan AJ. Pain from metastatic bone tumors. In: Aktolun C, Tauxe WN, eds. Nuclear Oncology. Berlin-Hiedelberg: Springer-Verlag, 1999:245.
3. 153Sm-EDTMP for bone pain palliation in skeletal metastsses. Eur J Nucl Med Mol Img 2004;31(Suppl. 1):S171.
4. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996;41:2027.
5. Twycross RG, Fairfield S. Pain in far advanced cancer. Pain 1982;14:303.
6. Daut RL, Cleeland CS. The prevalence of severity of pain in cancer. Cancer 1982;50:1913.
7. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 2003;29:321.
8. Hoskin PJ. Radiotherapy of bone pain. Pain 1995;63:137.
9. Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone - a preliminary report. J Nucl Med 1992;33:1437.
10. Deligny CL, Gelsema WJ, Tji TG, et al. Bone-seeking radiopharmaceuticals. Nucl Med Biol 1990;17:164.
11. Silberstein EB. Dosage and response in the radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 1996;37:249.
12. Knapp FF, Jr, Mirzadeh S, Beets AL, et al. Reactor produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot 1998;49:309.
13. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269.
14. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin Nucl Med 1992;22:11.
15. Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med 2001;31:330.
16. Johnson JC, Langhorst SM, Loyalka SK, et al. Calculation of radiation dose at a bone-to-marrow interface using Monte Carlo modeling techniques (ESG4). J Nucl Med 1992;33:623.
17. Cheung A, Driedger AA. Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of breast and prostate. Radiology 1980;134:209.
18. O'Mara RE. New P-32 compounds in therapy of bone lesions. In: Spencer RP, ed. Therapy in Nuclear Medicine. New York: Grune and Stratton, 1978:257.
19. Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 1987;14:219.
20. Shini J, Amir D, Soskolne WA, et al. Correlations between uptake of technetium, calcium, phosphate, and mineralization in rat tibial bone repair. J Nucl Med 1990;31:2011.
21. 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109.
22. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 1987;14:223.
23. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153-EDTMP in metastatic cancer. J Nucl Med 1989;30:1814.
24. Serafini AN. Systematic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Q J Nucl Med 2001;45:91.
25. de Klerk JMH, van het Schip AD, Zonnenberg BA, et al. Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996;37:244.
26. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 2002;23:67.
27. 3]octreotate. Eur J Nucl Med Mol Img 2003;30:417.
28. 177Lu-labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg Med Chem 2004;12:6077.
29. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447.
30. Firestone R, Shirley VS. In: Firestone R, Shirely VS, eds. Table of Isotopes, 8th ed. New York: John Wiely and Sons, 1996:2112.
31. 117mSn(4+) diethylenetriaminepentaacetic acid for radionuclidic therapy of bone cancer. J Nucl Med 2000;41:2043.
32. 186Re complexes of tetraphosphonate ligands and their pharmacological behaviour in animal models. Nucl Med Biol 2001;28:205.
33. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl Med Commun 1998;19:587.
34. 153Sm in rats. Appl Radiat Isot 1994;45:949.
35. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj Chem 2001;12:7.
36. Caravan P, Ellison JJ, McMurrym TJ, et al. Gadolinium(III) chelates as MRI constrast agents: Structure, dynamics, and applications. Chem Rev 1999;99:2293.
37. Lattimer JC, Corwin LA, Srapleton J, et al. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med 1990;31:586.
38. Awasthi V, Meinken G, Springer K, et al. Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J Virol 2004;78:6431.
39. Panagi Z, Beletsi A, Evangelatos G, et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001;221:143.
40. 177Lu-labeled metronidazole for possible use in targeting tumor hypoxia. Radiochim Acta 2006;94:375.
41. 177Lu-labeled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun 2006;27:661.